HEMOGENYX PHARMACEUTICALS PLC
Develops cell-based therapies for blood, autoimmune diseases, and viral infections.
HEMO | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYX3WZ24
- LEI:
- 2138008L93GYU5GN6179
- Country:
- United Kingdom
- Address:
- 6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON
- Website:
- https://hemogenyx.com/
- Sector:
- Manufacturing
Description
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops treatments for blood and autoimmune diseases, as well as viral infections. Its core technology includes advanced cell-based therapies, such as its proprietary Chimeric Antigen Receptor (CAR) T-cell platform, HEMO-CAR-T, which is being developed for the potential treatment of Acute Myeloid Leukemia (AML).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-19 08:00 |
Ultrafast CAR-T Manufacturing
|
English | 20.2 KB | ||
| 2024-12-12 23:43 |
Articles of Association of Hemogenyx Pharmaceuticals plc adopted on 9 December …
|
English | 380.0 KB | ||
| 2024-12-10 17:10 |
Admission of New Ordinary Shares and New ISIN
|
English | 13.9 KB | ||
| 2024-12-10 01:17 |
Resolutions passed at Extraordinary General Meeting of Hemogenyx Pharmaceutical…
|
English | 70.9 KB | ||
| 2024-12-09 14:30 |
Result of Extraordinary General Meeting
|
English | 21.7 KB | ||
| 2024-12-09 08:00 |
Site Initiation Visit Completed
|
English | 15.9 KB | ||
| 2024-12-06 08:00 |
CBR Macrophage Delivery Update
|
English | 16.1 KB | ||
| 2024-11-29 08:00 |
Total Voting Rights
|
English | 10.1 KB | ||
| 2024-11-22 17:06 |
Notice of General Meeting and Circular regarding share capital reorganisation
|
English | 140.9 KB | ||
| 2024-11-22 17:06 |
Notice of General Meeting and Circular regarding share capital reorganisation
|
English | 140.9 KB | ||
| 2024-11-22 13:49 |
Notice of Extraordinary General Meeting
|
English | 24.1 KB | ||
| 2024-11-22 08:00 |
IRB Approval for Phase I Clinical Trial
|
English | 17.9 KB | ||
| 2024-11-11 08:00 |
Institutional Investment
|
English | 12.4 KB | ||
| 2024-10-30 08:00 |
Schedule for Phase I Clinical Trial Opening
|
English | 16.9 KB | ||
| 2024-10-02 12:19 |
Strategic Investment from Prevail Partners, LLC
|
English | 21.9 KB |
Automate Your Workflow. Get a real-time feed of all HEMOGENYX PHARMACEUTICALS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for HEMOGENYX PHARMACEUTICALS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HEMOGENYX PHARMACEUTICALS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
